Polyethylenimine-Dextran-Coated Magnetic Nanoparticles Loaded with Mir-302B Suppress Osteosarcoma
            <i>In Vitro</i>
            and
            <i>In Vivo</i>

Gong, Ming; Liu, Huowen; Sun, Ningxiang; Xie, Yuanlong; Yan, F.; Cai, Lin

doi:10.2217/nnm-2019-0218

Cited by 33 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Under a magnetic field, cells were incubated with a vector‐magnetic particle mixture that attracted the particles into the cells 82 . The magnetic particles used were mainly superparamagnetic iron oxide nanoparticles, which were coated with highly biocompatible polymers, such as PEI, 83 glucan, 84 and poly(amidoamine) (PAMAM) dendritic macromolecules 85 . The results of magnetic transfection comprise the rapid deposition of a full‐dose vehicle on target cells, which further leads to a high percentage of cells being rapidly transfected within minutes 86 …”

Section: Exogenous Gene Transfer Methodsmentioning

confidence: 99%

Biomaterial‐based gene therapy

Gao

et al. 2023

MedComm

View full text Add to dashboard Cite

Gene therapy, a medical approach that involves the correction or replacement of defective and abnormal genes, plays an essential role in the treatment of complex and refractory diseases, such as hereditary diseases, cancer, and rheumatic immune diseases. Nucleic acids alone do not easily enter the target cells due to their easy degradation in vivo and the structure of the target cell membranes. The introduction of genes into biological cells is often dependent on gene delivery vectors, such as adenoviral vectors, which are commonly used in gene therapy. However, traditional viral vectors have strong immunogenicity while also presenting a potential infection risk. Recently, biomaterials have attracted attention for use as efficient gene delivery vehicles, because they can avoid the drawbacks associated with viral vectors. Biomaterials can improve the biological stability of nucleic acids and the efficiency of intracellular gene delivery. This review is focused on biomaterial‐based delivery systems in gene therapy and disease treatment. Herein, we review the recent developments and modalities of gene therapy. Additionally, we discuss nucleic acid delivery strategies, with a focus on biomaterial‐based gene delivery systems. Furthermore, the current applications of biomaterial‐based gene therapy are summarized.

show abstract

Section: Exogenous Gene Transfer Methodsmentioning

confidence: 99%

Biomaterial‐based gene therapy

Gao

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…It is a highly stable and hydrophilic polymer that has also been used in nanomedicine [ 128 ]. Various dextran-based nanocarriers with rational modifications, such as PEI-dextran-coated iron oxide nanoparticles [ 129 ], lipid-modified dextran-based polymeric nanoparticles [ 130 ], carboxymethyl dextran-stabilized PEI-PCL (poly(epsilon-caprolactone)) nanoparticles, and chitosan-thiolated dextran nanoparticles [ 127 ], have been used to deliver several miRNA therapeutics. In an interesting work conducted by Zheng et al [ 131 ], spermine-modified acetalated dextran nanoparticles (SpAcDex NPs) were synthesized, modified with bradykinin ligand agonist targeting B1 receptor, and encapsulated with anti-miR-21, aiming to upregulate PTEN for the treatment of glioblastoma multiforme (GBM).…”

Section: Nanocarrier Systems To Deliver Mirna-based Therapeuticsmentioning

confidence: 99%

miRacle of microRNA-Driven Cancer Nanotherapeutics

Kara

Arun

Calin

et al. 2022

Cancers

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are non-protein-coding RNA molecules 20–25 nucleotides in length that can suppress the expression of genes involved in numerous physiological processes in cells. Accumulating evidence has shown that dysregulation of miRNA expression is related to the pathogenesis of various human diseases and cancers. Thus, stragegies involving either restoring the expression of tumor suppressor miRNAs or inhibiting overexpressed oncogenic miRNAs hold potential for targeted cancer therapies. However, delivery of miRNAs to tumor tissues is a challenging task. Recent advances in nanotechnology have enabled successful tumor-targeted delivery of miRNA therapeutics through newly designed nanoparticle-based carrier systems. As a result, miRNA therapeutics have entered human clinical trials with promising results, and they are expected to accelerate the transition of miRNAs from the bench to the bedside in the next decade. Here, we present recent perspectives and the newest developments, describing several engineered natural and synthetic novel miRNA nanocarrier formulations and their key in vivo applications and clinical trials.

show abstract

“…They described that overexpression of miR-302b decreased the mRNA expression of YOD1 (direct target of miR-302b ), ICTH , and YAP1 . In contrast, LATS1 expression increased, suggesting that the YOD1-ICTH-LATS1-YAP axis is controlled by miR-302b [ 93 ].…”

Section: Deregulation Of the Hippo Signaling Pathway In Bone And Soft...mentioning

confidence: 99%

Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma

Salguero-Aranda

Olmedo-Pelayo

Álava

et al. 2022

Cancers

View full text Add to dashboard Cite

The Hippo pathway is an evolutionarily conserved modulator of developmental biology with a key role in tissue and organ size regulation under homeostatic conditions. Like other signaling pathways with a significant role in embryonic development, the deregulation of Hippo signaling contributes to oncogenesis. Central to the Hippo pathway is a conserved cascade of adaptor proteins and inhibitory kinases that converge and regulate the activity of the oncoproteins YAP and TAZ, the final transducers of the pathway. Elevated levels and aberrant activation of YAP and TAZ have been described in many cancers. Though most of the studies describe their pervasive activation in epithelial neoplasms, there is increasing evidence pointing out its relevance in mesenchymal malignancies as well. Interestingly, somatic or germline mutations in genes of the Hippo pathway are scarce compared to other signaling pathways that are frequently disrupted in cancer. However, in the case of sarcomas, several examples of genetic alteration of Hippo members, including gene fusions, have been described during the last few years. Here, we review the current knowledge of Hippo pathway implication in sarcoma, describing mechanistic hints recently reported in specific histological entities and how these alterations represent an opportunity for targeted therapy in this heterogeneous group of neoplasm.

show abstract

Polyethylenimine-Dextran-Coated Magnetic Nanoparticles Loaded with Mir-302B Suppress Osteosarcoma In Vitro and In Vivo

Cited by 33 publications

References 32 publications

Biomaterial‐based gene therapy

Biomaterial‐based gene therapy

miRacle of microRNA-Driven Cancer Nanotherapeutics

Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma

Contact Info

Product

Resources

About